Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Hepatic Impairment Clinical Trial

Official title:

A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04643795
• Other study ID #: MGL-3196-10
• Status: Completed
• Phase: Phase 1
• Start date: October 25, 2018
• Est. completion date: August 4, 2021

Study information

• Verified date: October 2023
• Source: Madrigal Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with normal hepatic function, including a subset of NASH subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: August 4, 2021
• Est. primary completion date: August 4, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Capable of understanding and willing and able to sign written informed consent

• Male or female, between 18 and 85 years of age (inclusive)

• BMI between 18 and 45 kg/m2 (inclusive)

• In healthy subjects with normal hepatic function:

• Considered by the Investigator to be healthy, based on medical and surgical history, physical examination including vital signs, 12-lead ECG, and laboratory test results

• Match demographically with a subject in the hepatically impaired population according to gender, BMI (±20%), and age (±10 years)

• In subjects with hepatic impairment:

• Considered by the Investigator to be clinically stable with respect to underlying HI, based on medical and surgical history, physical examination including vital signs, 12-lead ECG, and laboratory test results

• In subjects with NASH:

• Confirmed diagnosis of NASH suggested by historical data, which include a previous liver biopsy within the last 5 years prior to randomization with evidence of NASH.

• BMI =18 kg/m2

Exclusion Criteria:

• Any clinically significant concomitant disease or condition (including treatment for such conditions) that, in the opinion of the Investigator, could either interfere with the study drug, pose an unacceptable risk to the subject, or compromise interpretation of study data

• Gilbert's syndrome

• Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of study drug

• eGFR <60 mL/min/1.73 m2 based on Modification of Diet in Renal Disease (MDRD) equation

• Received an investigational drug or device from another study within 30 days (or 5 half-lives, whichever is longer) prior to study drug administration

• In healthy subjects with normal hepatic function:

• Systolic blood pressure outside the range of 90 to 150 mmHg, diastolic blood pressure outside the range of 40 to 95 mmHg or heart rate outside the range of 40 to 100 beats per minute (bpm)

• History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months prior to screening

• In subjects with hepatic impairment:

• Any non-hepatic acute or chronic condition (including, but not limited to, poorly controlled diabetes and encephalopathy Grade =3) that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study

• Acute exacerbation of HI or unstable hepatic function, as determined by the Investigator, 30 days prior to study drug administration

• Has had a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure performed

Related Conditions & MeSH terms

• Cirrhosis, Liver
• Fatty Liver
• Hepatic Impairment
• Liver Cirrhosis
• Liver Diseases
• NASH - Nonalcoholic Steatohepatitis
• Non-alcoholic Fatty Liver Disease

Intervention

Drug:
• MGL-3196
Once daily oral dose for 6 days

Locations

Country	Name	City	State
United States	Madrigal Research Center	Orlando	Florida
United States	Madrigal Research Center	Saint Paul	Minnesota
United States	Madrigal Research Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Madrigal Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma pharmacokinetics - Cmax	Cmax after administration	16 days
Primary	Plasma pharmacokinetics - Tmax	Tmax after administration	16 days
Primary	Plasma pharmacokinetics - AUC (0-last)	AUC (0-last) after administration	16 days
Primary	Plasma pharmacokinetics - t1/2	t1/2 after administration	16 days
Primary	Effect on the incidence of adverse events		16 days